Anti-HIV antibody-dependent activation of NK cells impairs NKp46 expression

Journal of Immunology

Volumn 192, Issue 1, 2014, Pages 308-315

  Parsons, Matthew S ^a   Tang, Chi Chang ^a   Jegaskanda, Sinthujan ^a   Center, Robert J ^a   Brooks, Andrew G ^a   Stratov, Ivan ^a,b   Kent, Stephen J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MELBOURNE SEXUAL HEALTH CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; ILOMASTAT; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRANULATION; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INNATE IMMUNITY; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

EID: 84891121586     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301247     Document Type: Article

References (54)

1. Kent, S. J., J. C. Reece, J. Petravic, A. Martyushev, M. Kramski, R. De Rose, D. A. Cooper, A. D. Kelleher, S. Emery, P. U. Cameron, et al. 2013. The search for an HIV cure: tackling latent infection. Lancet Infect. Dis. 13: 614-621.
2. Madhavi, V., S. J. Kent, and I. Stratov. 2012. HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality. Expert Rev. Clin. Immunol. 8: 767-774.
3. Wren, L., and S. J. Kent. 2011. HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Hum. Vaccin. 7: 466-473.
4. Lambotte, O., G. Ferrari, C. Moog, N. L. Yates, H. X. Liao, R. J. Parks, C. B. Hicks, K. Owzar, G. D. Tomaras, D. C. Montefiori, et al. 2009. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23: 897-906.
5. Wren, L. H., A. W. Chung, G. Isitman, A. D. Kelleher, M. S. Parsons, J. Amin, D. A. Cooper, I. Stratov, M. Navis, and S. J. Kent; ADCC study collaboration investigators. 2013. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 138: 116-123.
6. Banks, N. D., N. Kinsey, J. Clements, and J. E. Hildreth. 2002. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res. Hum. Retroviruses 18: 1197-1205.
7. Hessell, A. J., L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M. Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
8. Bonsignori, M., J. Pollara, M. A. Moody, M. D. Alpert, X. Chen, K. K. Hwang, P. B. Gilbert, Y. Huang, T. C. Gurley, D. M. Kozink, et al. 2012. Antibodydependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86: 11521-11532.
9. Haynes, B. F., P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366: 1275-1286.
10. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al; MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
11. Ljunggren, K., A. Karlson, E. M. Fenyo, and M. Jondal. 1989. Natural and antibody-dependent cytotoxicity in different stages of human immunodeficiency virus type 1 infection. Clin. Exp. Immunol. 75: 184-189.
12. Alter, G., N. Teigen, B. T. Davis, M. M. Addo, T. J. Suscovich, M. T. Waring, H. Streeck, M. N. Johnston, K. D. Staller, M. T. Zaman, et al. 2005. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 106: 3366-3369.
13. Parasa, V. R., R. Sikhamani, and A. Raja. 2012. Effect of recombinant cytokines on the expression of natural killer cell receptors from patients with TB or/and HIV infection. PLoS ONE 7: e37448.
14. Brenner, B. G., C. Gryllis, and M. A. Wainberg. 1991. Role of antibodydependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J. Leukoc. Biol. 50: 628-640.
15. De Maria, A., M. Fogli, P. Costa, G. Murdaca, F. Puppo, D. Mavilio, A. Moretta, and L. Moretta. 2003. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur. J. Immunol. 33: 2410-2418.
16. Fauci, A. S., D. Mavilio, and S. Kottilil. 2005. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat. Rev. Immunol. 5: 835-843.
17. Jia, M., D. Li, X. He, Y. Zhao, H. Peng, P. Ma, K. Hong, H. Liang, and Y. Shao. 2013. Impaired natural killer cell-induced antibody-dependent cell-mediated cytotoxicity is associated with human immunodeficiency virus-1 disease progression. Clin. Exp. Immunol. 171: 107-116.
18. Lichtfuss, G. F., W. J. Cheng, Y. Farsakoglu, G. Paukovics, R. Rajasuriar, P. Velayudham, M. Kramski, A. C. Hearps, P. U. Cameron, S. R. Lewin, et al. 2012. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J. Immunol. 189: 1491-1499.
19. Liu, Q., Y. Sun, S. Rihn, A. Nolting, P. N. Tsoukas, S. Jost, K. Cohen, B. Walker, and G. Alter. 2009. Matrix metalloprotease inhibitors restore impaired NK cellmediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J. Virol. 83: 8705-8712.
20. Mavilio, D., J. Benjamin, M. Daucher, G. Lombardo, S. Kottilil, M. A. Planta, E. Marcenaro, C. Bottino, L. Moretta, A. Moretta, and A. S. Fauci. 2003. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc. Natl. Acad. Sci. USA 100: 15011-15016.
21. Mavilio, D., G. Lombardo, J. Benjamin, D. Kim, D. Follman, E. Marcenaro, M. A. O'Shea, A. Kinter, C. Kovacs, A. Moretta, and A. S. Fauci. 2005. Characterization of CD562/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc. Natl. Acad. Sci. USA 102: 2886-2891.
22. Ziegner, U., D. Campbell, K. Weinhold, I. Frank, R. Rutstein, and S. E. Starr. 1999. Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection. Clin. Diagn. Lab. Immunol. 6: 718-724.
23. Long, E. O., H. S. Kim, D. Liu, M. E. Peterson, and S. Rajagopalan. 2013. Controlling natural killer cell responses: Integration of signals for activation and inhibition. Annu. Rev. Immunol. 31: 227-258.
24. Gazit, R., R. Gruda, M. Elboim, T. I. Arnon, G. Katz, H. Achdout, J. Hanna, U. Qimron, G. Landau, E. Greenbaum, et al. 2006. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat. Immunol. 7: 517-523.
25. Glasner, A., H. Ghadially, C. Gur, N. Stanietsky, P. Tsukerman, J. Enk, and O. Mandelboim. 2012. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J. Immunol. 188: 2509-2515.
26. Zhou, Q., A. Gil-Krzewska, G. Peruzzi, and F. Borrego. 2013. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. Clin. Exp. Immunol. 173: 131-139.
27. Cavalcanti, M., A. Jewett, and B. Bonavida. 1999. Irreversible cancer cellinduced functional anergy and apoptosis in resting and activated NK cells. Int. J. Oncol. 14: 361-366.
28. Grzywacz, B., N. Kataria, and M. R. Verneris. 2007. CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 21: 356-359, author reply 359.
29. Jewett, A., M. Cavalcanti, J. Giorgi, and B. Bonavida. 1997. Concomitant killing in vitro of both gp120-coated CD4+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system. J. Immunol. 158: 5492-5500.
30. Hanna, J., T. Gonen-Gross, J. Fitchett, T. Rowe, M. Daniels, T. I. Arnon, R. Gazit, A. Joseph, K. W. Schjetne, A. Steinle, et al. 2004. Novel APC-like properties of human NK cells directly regulate T cell activation. J. Clin. Invest. 114: 1612-1623.
31. Ward, J., M. Bonaparte, J. Sacks, J. Guterman, M. Fogli, D. Mavilio, and E. Barker. 2007. HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts. Blood 110: 1207-1214.
32. Champsaur, M., and L. L. Lanier. 2010. Effect of NKG2D ligand expression on host immune responses. Immunol. Rev. 235: 267-285.
33. Chung, A. W., E. Rollman, R. J. Center, S. J. Kent, and I. Stratov. 2009. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J. Immunol. 182: 1202-1210.
34. Stratov, I., A. Chung, and S. J. Kent. 2008. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIVinfected subjects. J. Virol. 82: 5450-5459.
35. Madhavi, V., M. Navis, A. W. Chung, G. Isitman, L. H. Wren, R. De Rose, S. J. Kent, and I. Stratov. 2013. Activation of NK cells by HIV-specific ADCC antibodies: Role for granulocytes in expressing HIV-1 peptide epitopes. Hum. Vaccin. Immunother. 9: 1011-1018.
36. Center, R. J., A. K. Wheatley, S. M. Campbell, A. J. Gaeguta, V. Peut, S. Alcantara, C. Siebentritt, S. J. Kent, and D. F. Purcell. 2009. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 27: 6605-6612.
37. Achdout, H., T. Meningher, S. Hirsh, A. Glasner, Y. Bar-On, C. Gur, A. Porgador, M. Mendelson, M. Mandelboim, and O. Mandelboim. 2010. Killing of avian and Swine influenza virus by natural killer cells. J. Virol. 84: 3993-4001.
38. Lichtfuss, G. F., A. C. Meehan, W. J. Cheng, P. U. Cameron, S. R. Lewin, S. M. Crowe, and A. Jaworowski. 2011. HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity. J. Leukoc. Biol. 89: 149-158.
39. Jost, S., J. Reardon, E. Peterson, D. Poole, R. Bosch, G. Alter, and M. Altfeld. 2011. Expansion of 2B4+ natural killer (NK) cells and decrease in NKp46+ NK cells in response to influenza. Immunology 132: 516-526.
40. Pollara, J., L. Hart, F. Brewer, J. Pickeral, B. Z. Packard, J. A. Hoxie, A. Komoriya, C. Ochsenbauer, J. C. Kappes, M. Roederer, et al. 2011. Highthroughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79: 603-612.
41. Smalls-Mantey, A., N. Doria-Rose, R. Klein, A. Patamawenu, S. A. Migueles, S. Y. Ko, C.W. Hallahan, H. Wong, B. Liu, L. You, et al. 2012. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J. Virol. 86: 8672-8680.
42. Ward, J. P., M. I. Bonaparte, and E. Barker. 2004. HLA-C and HLA-E reduce antibody-dependent natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. AIDS 18: 1769-1779.
43. O'Connor, G. M., A. Holmes, F. Mulcahy, and C. M. Gardiner. 2007. Natural Killer cells from long-term non-progressor HIV patients are characterized by altered phenotype and function. Clin. Immunol. 124: 277-283.
44. Forthal, D. N., G. Landucci, and E. S. Daar. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75: 6953-6961.
45. Martin, M. P., Y. Qi, X. Gao, E. Yamada, J. N. Martin, F. Pereyra, S. Colombo, E. E. Brown, W. L. Shupert, J. Phair, et al. 2007. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39: 733-740.
46. Boulet, S., R. Song, P. Kamya, J. Bruneau, N. H. Shoukry, C. M. Tsoukas, and N. F. Bernard. 2010. HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells. J. Immunol. 184: 2057-2064.
47. Parsons, M. S., S. Boulet, R. Song, J. Bruneau, N. H. Shoukry, J. P. Routy, C. M. Tsoukas, and N. F. Bernard. 2010. Mind the gap: lack of association between KIR3DL1004/HLA-Bw4-induced natural killer cell function and protection from HIV infection. J. Infect. Dis. 202(Suppl. 3): S356-S360.
48. Parsons, M. S., L. Wren, G. Isitman, M. Navis, I. Stratov, N. F. Bernard, and S. J. Kent. 2012. HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti- HIV antibody-dependent cellular cytotoxicity. J. Virol. 86: 4488-4495.
49. Alter, G., S. Rihn, K. Walter, A. Nolting, M. Martin, E. S. Rosenberg, J. S. Miller, M. Carrington, and M. Altfeld. 2009. HLA class I subtypedependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J. Virol. 83: 6798-6805.
50. Hatjiharissi, E., L. Xu, D. D. Santos, Z. R. Hunter, B. T. Ciccarelli, S. Verselis, M. Modica, Y. Cao, R. J. Manning, X. Leleu, et al. 2007. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcgammaRIIIa-158 V/V and V/F polymorphism. Blood 110: 2561-2564.
51. Poonia, B., G. H. Kijak, and C. D. Pauza. 2010. High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS ONE 5: e15562.
52. Kijak, G., S. Li, R. Paris, V. Ngauy, N. Michael, S. Rerks-Ngarm, P. Gilbert P, and J. Kim. 2012. Modulation of Vaccine Effect by FcG Receptor 3a Genetic Polymorphism in RV144. In 19th Conference on Retroviruses and Opportunistic Infections. Seattle.
53. Forthal, D. N., G. Landucci, J. Bream, L. P. Jacobson, T. B. Phan, and B. Montoya. 2007. FcgammaRIIa genotype predicts progression of HIV infection. J. Immunol. 179: 7916-7923.
54. Ackerman, M. E., M. Crispin, X. Yu, K. Baruah, A. W. Boesch, D. J. Harvey, A. S. Dugast, E. L. Heizen, A. Ercan, I. Choi, et al. 2013. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123: 2183-2192.